PITTSBURGH, April 18, 2005 /PRNewswire-FirstCall via COMTEX/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Anagrelide Hydrochloride Capsules, 0.5 mg (base) and 1 mg (base). Anagrelide HCl Capsules are the generic version of Shire Laboratories, Inc.'s Agrylin^® Capsules.

Mylan will ship the product immediately.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories, Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com .

This press release includes statements that constitute "forward-looking statements," including with regard to the immediate shipment of Anagrelide Hydrochloride. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward- looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the possible negative effects of any interruption of manufacture of the product; uncertainties regarding market acceptance and demand for the product; dependence on third-party suppliers and distributors for raw materials; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

SOURCE Mylan Laboratories Inc.

Media, Heather Bresch, or Investors, Kris King, both of Mylan Laboratories Inc., +1-724-514-1800